Statin intolerance

American Journal of Cardiology

Volumn 113, Issue 10, 2014, Pages 1765-1771

  Ahmad, Zahid ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTIN; CIMETIDINE; CLARITHROMYCIN; CREATINE KINASE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

APHERESIS; CHOLESTEROL SYNTHESIS; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; HISTORY; HUMAN; LIFESTYLE MODIFICATION; MYALGIA; MYOPATHY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

CREATINE KINASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MUSCULAR DISEASES;

EID: 84899717977     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.02.033     Document Type: Review

References (45)

1. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 Nov 12 [Epub ahead of print]
2. P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, B.J. Kimura, G.D. Vladutiu, J.D. England Scripps Mercy Clinical Research C Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
3. G.B. Mancini, S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, J. Genest, M. Gupta, R.A. Hegele, D. Ng, and J. Pope Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
4. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation 106 2002 1024 1028
5. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
6. G.D. Vladutiu, P.J. Isackson, K. Kaufman, J.B. Harley, B. Cobb, L. Christopher-Stine, and R.L. Wortmann Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies Mol Genet Metab 104 2011 167 173
7. A. Kashani, C.O. Phillips, J.M. Foody, Y. Wang, S. Mangalmurti, D.T. Ko, and H.M. Krumholz Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
8. E. Bjornsson, E.I. Jacobsen, and E. Kalaitzakis Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing J Hepatol 56 2012 374 380
9. A. Yamamoto, H. Sudo, and A. Endo Therapeutic effects of ML-236B in primary hypercholesterolemia Atherosclerosis 35 1980 259 266
10. C. East, P.A. Alivizatos, S.M. Grundy, P.H. Jones, and J.A. Farmer Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation N Engl J Med 318 1988 47 48
11. D.J. Norman, D.R. Illingworth, J. Munson, and J. Hosenpud Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin N Engl J Med 318 1988 46 47
12. J.A. Staffa, J. Chang, and L. Green Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 346 2002 539 540
13. R.P. Mason Molecular basis of differences among statins and a comparison with antioxidant vitamins Am J Cardiol 98 2006 34P 41P
14. B.A. Parker, J.A. Capizzi, A.S. Grimaldi, P.M. Clarkson, S.M. Cole, J. Keadle, S. Chipkin, L.S. Pescatello, K. Simpson, C.M. White, and P.D. Thompson The effect of statins on skeletal muscle function Circulation 2012
15. K.E. Hansen, J.P. Hildebrand, E.E. Ferguson, and J.H. Stein Outcomes in 45 patients with statin-associated myopathy Arch Intern Med 165 2005 2671 2676
16. G.D. Vladutiu, Z. Simmons, P.J. Isackson, M. Tarnopolsky, W.L. Peltier, A.C. Barboi, N. Sripathi, R.L. Wortmann, and P.S. Phillips Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34 2006 153 162
17. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
18. FDA Public Health Advisory for Crestor (rosuvastatin). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051756. htm, Access Date: February 18, 2014
19. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
20. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner American Heart Association Statistics C, Stroke Statistics S Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
21. B.A. Golomb, J.J. McGraw, M.A. Evans, and J.E. Dimsdale Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance Drug Saf 30 2007 669 675
22. B.A. Parker, A.L. Augeri, J.A. Capizzi, K.D. Ballard, C. Troyanos, A.L. Baggish, P.A. D'Hemecourt, and P.D. Thompson Effect of statins on creatine kinase levels before and after a marathon run Am J Cardiol 109 2012 282 287
23. M.G. Mohaupt, R.H. Karas, E.B. Babiychuk, V. Sanchez-Freire, K. Monastyrskaya, L. Iyer, H. Hoppeler, F. Breil, and A. Draeger Association between statin-associated myopathy and skeletal muscle damage CMAJ 181 2009 E11 E18
24. C.R. Mikus, L.J. Boyle, S.J. Borengasser, D.J. Oberlin, S.P. Naples, J. Fletcher, G.M. Meers, M. Ruebel, M.H. Laughlin, K.C. Dellsperger, P.J. Fadel, and J.P. Thyfault Simvastatin impairs exercise training adaptations J Am Coll Cardiol 2013
25. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237
26. G. Caso, P. Kelly, M.A. McNurlan, and W.E. Lawson Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins Am J Cardiol 99 2007 1409 1412
27. A. Gupta, and P.D. Thompson The relationship of vitamin D deficiency to statin myopathy Atherosclerosis 215 2011 23 29
28. M. Niemi, M.K. Pasanen, and P.J. Neuvonen Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol Rev 63 2011 157 181
29. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop, and R. Collins SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
30. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, R.J. Prineas, and W. Friedewald Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
31. B.M. Rifkind Lipid Research Clinics Coronary Primary Prevention Trial: results and implications Am J Cardiol 54 1984 30C 34C
32. S.M. Grundy Statin discontinuation and intolerance: the challenge of lifelong therapy Ann Intern Med 158 2013 562 563
33. A. Pineda, and L.X. Cubeddu Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep 13 2011 23 30
34. H. Zhang, J. Plutzky, S. Skentzos, F. Morrison, P. Mar, M. Shubina, and A. Turchin Discontinuation of statins in routine care settings: a cohort study Ann Intern Med 158 2013 526 534
35. E.A. Stein, C.M. Ballantyne, E. Windler, P.A. Sirnes, A. Sussekov, Z. Yigit, C. Seper, and C.R. Gimpelewicz Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 2008 490 496
36. C.J. Glueck, D. Aregawi, M. Agloria, Q. Khalil, M. Winiarska, J. Munjal, S. Gogineni, and P. Wang Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies Clin Ther 28 2006 933 942
37. M.S. Matalka, M.C. Ravnan, and P.C. Deedwania Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) Am Heart J 144 2002 674 677
38. S.P. Kennedy, G.P. Barnas, M.J. Schmidt, M.S. Glisczinski, and A.C. Paniagua Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance J Clin Lipidol 5 2011 308 315
39. J.M. Backes, C.A. Gibson, J.F. Ruisinger, and P.M. Moriarty The high-dose rosuvastatin once weekly study (the HD-ROWS) J Clin Lipidol 6 2012 362 367
40. H. Slim, and P.D. Thompson Ezetimibe-related myopathy: a systematic review J Clin Lipidol 2 2008 328 334
41. C.V. Venero, J.V. Venero, R.L. Seip, and P.D. Thompson Effectiveness of thrice weekly ezetimibe Am J Cardiol 102 2008 1205 1206
42. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, and J. Wittes Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
43. G.R. Thompson, and H.-U.L.A.W. Group Recommendations for the use of LDL apheresis Atherosclerosis 198 2008 247 255
44. S.C. Halbert, B. French, R.Y. Gordon, J.T. Farrar, K. Schmitz, P.B. Morris, P.D. Thompson, D.J. Rader, and D.J. Becker Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2010 198 204
45. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 830 839 W147-839